title: Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats.
abstract: OBJECTIVE
  To evaluate the effect of resveratrol on an experimentally induced endometriosis rat model.
  
  
  METHODS
  After endometriotic implants were surgically formed, rats were randomly divided into 2 groups as control group (saline treated, n = 6) and resveratrol group (10 mg/kg/d, n = 6). The inflammatory markers and histopathological changes were assessed at the end of the treatment period. Results Our results showed (1) significant reduction in the implant size (P < .0005); (2) significantly decreased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid and plasma (P < .005); and monocyte chemotactic protein 1 (MCP-1) in the peritoneal fluid (P < .05), (3) highly significant suppression of VEGF expression in the endometriotic tissue (P < .0005); and (4) considerable histological changes in the endometriotic foci following resveratrol treatment.
  
  
  CONCLUSIONS
  Resveratrol appears to be effective on the development of endometriosis through its antiangiogenic and anti-inflammatory properties. Future studies with different doses of resveratrol might provide more comprehensive results regarding the treatment of endometriosis.
authors.affiliation: 1Department of Obstetrics and Gynaecology, Ege University School of Medicine, Izmir, Turkey.
authors.forename: Ahmet Mete
authors.initials: AM
authors.lastname: Ergenoğlu
authors.forename: Ahmet Özgür
authors.initials: AÖ
authors.lastname: Yeniel
authors.forename: Oytun
authors.initials: O
authors.lastname: Erbaş
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Aktuğ
authors.forename: Nuri
authors.initials: N
authors.lastname: Yildirim
authors.forename: Murat
authors.initials: M
authors.lastname: Ulukuş
authors.forename: Dilek
authors.initials: D
authors.lastname: Taskiran
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology*; D004717:Endometrium / Q000187:drug effects / Q000473:pathology*; D005260:Female; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012074:Remission Induction / Q000379:methods; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D013267:Stilbenes; D000077185:Resveratrol
keywords: MCP-1; TNF-α; VEGF; cytokines; endometriosis; resveratrol